- Home
- FNGR vs ACET Comparison
FNGR vs ACET Comparison
Compare FNGR & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNGR
- ACET
- Stock Information
- Founded
- FNGR 2016
- ACET 1947
- Country
- FNGR Singapore
- ACET United States
- Employees
- FNGR N/A
- ACET N/A
- Industry
- FNGR Computer Software: Prepackaged Software
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- FNGR Technology
- ACET Health Care
- Exchange
- FNGR Nasdaq
- ACET Nasdaq
- Market Cap
- FNGR 108.1M
- ACET 93.1M
- IPO Year
- FNGR N/A
- ACET N/A
- Fundamental
- Price
- FNGR $2.08
- ACET $0.96
- Analyst Decision
- FNGR
- ACET Strong Buy
- Analyst Count
- FNGR 0
- ACET 4
- Target Price
- FNGR N/A
- ACET $5.67
- AVG Volume (30 Days)
- FNGR 205.1K
- ACET 790.0K
- Earning Date
- FNGR 01-14-2025
- ACET 11-06-2024
- Dividend Yield
- FNGR N/A
- ACET N/A
- EPS Growth
- FNGR N/A
- ACET N/A
- EPS
- FNGR N/A
- ACET N/A
- Revenue
- FNGR $31,176,174.00
- ACET N/A
- Revenue This Year
- FNGR $260.03
- ACET N/A
- Revenue Next Year
- FNGR N/A
- ACET N/A
- P/E Ratio
- FNGR N/A
- ACET N/A
- Revenue Growth
- FNGR N/A
- ACET N/A
- 52 Week Low
- FNGR $1.63
- ACET $0.89
- 52 Week High
- FNGR $4.36
- ACET $3.77
- Technical
- Relative Strength Index (RSI)
- FNGR 52.93
- ACET 37.36
- Support Level
- FNGR $1.95
- ACET $0.91
- Resistance Level
- FNGR $2.70
- ACET $1.12
- Average True Range (ATR)
- FNGR 0.12
- ACET 0.09
- MACD
- FNGR 0.02
- ACET 0.00
- Stochastic Oscillator
- FNGR 22.50
- ACET 16.21
About FNGR FingerMotion Inc.
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company business line includes Telecommunications Products and Services; Value Added Products and Services; Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Big Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.